Bronchopulmonary Dysplasia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight

The Bronchopulmonary Dysplasia market size was valued approximately USD 0.028 million in 2023 to grow with a rapid CAGR during the study period (2020-2034).

LAS VEGAS, NEVADA, UNITED STATES, July 3, 2024 /EINPresswire.com/ --
DelveInsight’s “Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchopulmonary Dysplasia Market Forecast

Some of the key facts of the Bronchopulmonary Dysplasia Market Report:
The Bronchopulmonary Dysplasia market size was valued approximately USD 0.028 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the total number of incident cases of Bronchopulmonary Dysplasia (BPD) in the 7MM was approximately 17,091. It is projected that these cases will rise by the year 2032.
In 2023, the United States reported the highest number of incident cases of Bronchopulmonary Dysplasia (BPD) among the 7MM, totaling around 13,276 cases.
In the EU4 countries and the UK, Germany reported the highest incidence of Bronchopulmonary Dysplasia (BPD) with 930 cases in 2023, followed closely by France with 920 cases. In contrast, Spain had the lowest incidence of BPD in the same year.
According to DelveInsight’s analysts, assessments indicate that in the United States, there were about 5,225 cases of Bronchopulmonary Dysplasia (BPD) among preterm infants weighing ≤750 g, followed by 5,043 cases in the 751-1000 g group, 2,300 cases in the 1001-1250 g group, and 709 cases in the ≥1250 g group in 2023.
Currently, the Bronchopulmonary Dysplasia pipeline is sparse, featuring primarily OHB607 (mecasermin rinfabate), an intravenous infusion under development by Oak Hill. Additional developments include PNEUMOSTEM (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) by Medipost, and AT-100 by Airway Therapeutics, among others.
Key Bronchopulmonary Dysplasia Companies: Medipost Co, Oak Hill Bio/Takeda, Chiesi Farmaceutici, PNEUMOSTEM, Airway Therapeutics, Emmes Company, Medipost Co Ltd., Chiesi Pharmaceuticals, Mallinckrodt, Abbott, Shire, and others
Key Bronchopulmonary Dysplasia Therapies: PNEUMOSTEM^®, OHB-607, CHF5633, Medipost, AT-100, Furosemide Cohort, PNEUMOSTEM^®, Curosurf, Infasurf, palivizumab, rhIGF-I/rhIGFBP-3, and others
The Bronchopulmonary Dysplasia epidemiology based on gender analyzed that the severity‐specific data reveal the highest number of preterm infants have mild Bronchopulmonary Dysplasia
The Bronchopulmonary Dysplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchopulmonary Dysplasia pipeline products will significantly revolutionize the Bronchopulmonary Dysplasia market dynamics.

Bronchopulmonary Dysplasia Overview
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants, especially those born very prematurely or with low birth weight. It typically develops in infants who have received mechanical ventilation and oxygen therapy for acute respiratory distress syndrome (ARDS) or other conditions shortly after birth.

Get a Free sample for the Bronchopulmonary Dysplasia Market Report:
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Bronchopulmonary Dysplasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bronchopulmonary Dysplasia Epidemiology Segmentation:
The Bronchopulmonary Dysplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Incident cases of Bronchopulmonary Dysplasia in the 7MM
Weight-specific cases of Bronchopulmonary Dysplasia in the 7MM
Severity-specific cases of Bronchopulmonary Dysplasia in the 7MM

Download the report to understand which factors are driving Bronchopulmonary Dysplasia epidemiology trends @ Bronchopulmonary Dysplasia Epidemiology Forecast

Bronchopulmonary Dysplasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched during the study period. The analysis covers Bronchopulmonary Dysplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchopulmonary Dysplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bronchopulmonary Dysplasia Therapies and Key Companies
PNEUMOSTEM^®: Medipost Co
OHB-607: Oak Hill Bio/Takeda
CHF5633: Chiesi Farmaceutici
Medipost: PNEUMOSTEM
AT-100: Airway Therapeutics
Furosemide Cohort: Emmes Company
PNEUMOSTEM^®: Medipost Co Ltd.
Curosurf: Chiesi Farmaceuticials
Infasurf : Mallinckrodt
palivizumab: Abbott
rhIGF-I/rhIGFBP-3: Shire

Bronchopulmonary Dysplasia Market Drivers
Improved disease understanding
Increase in Bronchopulmonary Dysplasia patient pool
Biomarkers
Limited late-stage drugs in the pipeline

Bronchopulmonary Dysplasia Market Barriers
The discrepancy in Epidemiology Data
Lack of adequate clinical data
High use of Non-pharmacological therapy
Limitations in Animal Models

Scope of the Bronchopulmonary Dysplasia Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Bronchopulmonary Dysplasia Companies: Medipost Co, Oak Hill Bio/Takeda, Chiesi Farmaceutici, PNEUMOSTEM, Airway Therapeutics, Emmes Company, Medipost Co Ltd., Chiesi Pharmaceuticals, Mallinckrodt, Abbott, Shire, and others
Key Bronchopulmonary Dysplasia Therapies: PNEUMOSTEM^®, OHB-607, CHF5633, Medipost, AT-100, Furosemide Cohort, PNEUMOSTEM^®, Curosurf, Infasurf (ONY Inc.),
palivizumab, rhIGF-I/rhIGFBP-3, and others
Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies
Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Bronchopulmonary Dysplasia Unmet Needs, KOL’s views, Analyst’s views, Bronchopulmonary Dysplasia Market Access and Reimbursement

To know more about Bronchopulmonary Dysplasia companies working in the treatment market, visit @ Bronchopulmonary Dysplasia Clinical Trials and Therapeutic Assessment

Table of Contents
1. Bronchopulmonary Dysplasia Market Report Introduction
2. Executive Summary for Bronchopulmonary Dysplasia
3. SWOT analysis of Bronchopulmonary Dysplasia
4. Bronchopulmonary Dysplasia Patient Share (%) Overview at a Glance
5. Bronchopulmonary Dysplasia Market Overview at a Glance
6. Bronchopulmonary Dysplasia Disease Background and Overview
7. Bronchopulmonary Dysplasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Bronchopulmonary Dysplasia
9. Bronchopulmonary Dysplasia Current Treatment and Medical Practices
10. Bronchopulmonary Dysplasia Unmet Needs
11. Bronchopulmonary Dysplasia Emerging Therapies
12. Bronchopulmonary Dysplasia Market Outlook
13. Country-Wise Bronchopulmonary Dysplasia Market Analysis (2020–2034)
14. Bronchopulmonary Dysplasia Market Access and Reimbursement of Therapies
15. Bronchopulmonary Dysplasia Market Drivers
16. Bronchopulmonary Dysplasia Market Barriers
17. Bronchopulmonary Dysplasia Appendix
18. Bronchopulmonary Dysplasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here